Clinical studies targeting genes associated with pro-inflammatory pathways, such as apoptosis signaling kinase-1 (ASK1) and C-C motif chemokine receptor 2 (CCR2)30–32, have been shown to improve NASH and control the progression of fibrosis, and there is great interest in the identification of additional inflammatory targets for potential therapies. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.